News1

Hyundai and Kia surpassed 500,000 sales in the U.S. in Q3, boosted by hybrid vehicles despite a drop in electric car sales.

GC Biopharma presented key research findings on its mRNA-LNP platform at the GCT 2026 summit and the Korean Bioengineering Society conference.

Parma Research successfully concluded the Rejuran Regeneration Roadshow Paris at the Salomon de Rothschild hotel on September 24.

SK Biopharmaceuticals' U.S. subsidiary, SK Life Science, held a meeting in Chicago to enhance execution and commercialization capabilities.

Huons announced that two non-clinical research results of its drug candidates were selected for the latest innovative abstracts (LBA).

The subcutaneous formulation of the global blockbuster immunotherapy Keytruda has officially launched in the domestic market.

Researchers uncover key genetic pathways causing metastasis and resistance in head and neck squamous cell carcinoma, proposing new combination therapies.

Samsung Bioepis and Teva are partnering to develop and commercialize two immune-disease biosimilars in the U.S., Europe, and Canada.

Daim Bio’s DM5167 has received FDA Fast Track designation for patients with advanced salivary gland cancer, supporting accelerated development of its selective PARP1 inhibitor in the U.S.

SK Bioscience marks two years since acquiring IDT Biologika, enhancing its global CDMO capabilities with its own vaccines.Two years after acquiring IDT Biologika, SK Bioscience has improved the German CDMO’s profitability and expanded joint global projects, while integrating its own vaccine production remains a key next step.

I-Mab Biologics will present clinical and preclinical data on IMB-101, a bispecific antibody being developed for hidradenitis suppurativa, at EADV 2026 in Vienna.

NIBEC is accelerating its push into Europe with MDR-certified regenerative biomaterials while exploring expanded partnerships with major global dental and implant companies.

Daewoong Pharm is expanding into healthcare data security by supplying hospitals and clinics with a distributed backup and recovery solution designed to protect critical medical data from cyberattacks.

A Korean real-world study found that switching bipolar disorder patients to lurasidone was associated with modest weight loss, improved depressive symptoms, and no reported serious adverse events over 16 weeks.